Frontlight ResearchEarly access
Spinal muscular atrophy trials in Brazil
2 of 3 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
- Where
- Distrito Federal, Porto Alegre, Sai Paula, São Paulo
- Age
- 0 days to 42 days
- People
- 30 worldwide
- Run by
- Biogen
See details and how to joinNCT07221669 · EU 2025-524054-34-00 - Phase 1/2Taking peopleStudy of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1
- Where
- Porto Alegre
- Age
- 2 weeks to 12 months
- People
- 22
- Run by
- Gemma Biotherapeutics
See details and how to joinNCT07070999